Early MASH risk stratification, drug choice, and aligned coverage could improve outcomes, explained Zobair Younossi, MD.
|Articles|April 15, 2008
The American Journal of Managed Care
- April 2008
- Volume 14
- Issue 4
Furst, DE; Khanna, D. (Am J Manag Care. 2007;13[suppl 9]:S216-S217)
Advertisement
After the publication of our December 2007 supplement, “Health-related Quality of Life in Rheumatoid Arthritis,” the Editors learned that several authors were not given the opportunity to review the final proofs of their manuscripts. As a result, errors were subsequently identified. The co-author’s name was inadvertently omitted from the Introduction. The correct byline for the Introduction should read: Daniel E. Furst, MD, and Dinesh Khanna, MD.
Click here
to view the corrected version of this article.
Articles in this issue
over 18 years ago
Furst DE, Khanna D. (Am J Manag Care. 2007;13[suppl 9]:S216-S217.over 18 years ago
Strand V, Singh JA. (Am J Manag Care. 2007;[suppl 9]:S237-S251.over 18 years ago
Strand V, Singh JA. (Am J Manag Care. 2007;13[suppl 9]:S237-S251)over 18 years ago
Association of Insurance Coverage With Chlamydia ScreeningAdvertisement
Related to this article
The Franklin County death is under state review as Pennsylvania's measles outbreak passed 1100 cases and 219 hospitalizations.
Among 4378 Spanish registry patients, dyshidrotic eczema was less tied to occupation than other hand eczema.
New non-CF bronchiectasis in Medicare is tied to high health care use and $8998 PPPM FFS spending; prevalence is highest in older women.
Understanding the Potential Risks of Prescription Drug Affordability Boards and Upper Payment Limits
NPC researchers examined questions about how these policies could affect patients, pharmacies, and providers.
The expanded indication rests on evidence extrapolated from carcinoma in situ, a new FDA approach to closely related forms of bladder cancer.
A historical review traces Sjögren disease from its early descriptions to the use of salivary gland ultrasound in diagnosis.
These phase 3 EXCALIBER-RRMM findings build on earlier MRD-negative complete response results supporting FDA approval of the iberdomide-based regimen.
Advertisement
Advertisement
Trending on AJMC
1
CMS Rule Ends Medicaid, CHIP Funding for Pediatric Gender Care
2
Oral JAK Inhibitors Boost Hair Regrowth Odds in Alopecia Areata
3
Coroner Reports Pennsylvania's Sixth Measles-Associated Death
4
Panel Calls for Earlier Detection, Clearer Pathways in Rare Glomerular Disease
5